Aims. Treatment outcomes for methicillin-resistant Staphylococcus aureus (MRSA) periprosthetic
Aims. Periprosthetic
Aims. The aim of this study was to estimate the 90-day periprosthetic
Aims. In cases of severe periprosthetic
Aims. Fungal and mycobacterial periprosthetic
Aims. Debridement, antibiotics, and implant retention (DAIR) remains one option for the treatment of acute periprosthetic
Aims. The preoperative diagnosis of periprosthetic
Aims. As a proven and comprehensive molecular technique, metagenomic next-generation sequencing (mNGS) has shown its potential in the diagnosis of pathogens in patients with periprosthetic
Aims. The outcome of repeat septic revision after a failed one-stage exchange for periprosthetic
Aims. Synovial fluid white blood cell (WBC) count and percentage of polymorphonuclear cells (%PMN) are elevated at periprosthetic
Aims. To describe the risk of periprosthetic
Aims. Calprotectin (CLP) is produced in neutrophils and monocytes and released into body fluids as a result of inflammation or infection. The aim of this study was to evaluate the utility of blood and synovial CLP in the diagnosis of chronic periprosthetic
Aims. The diagnosis of periprosthetic
Aims. Metagenomic next-generation sequencing (mNGS) is useful in the diagnosis of infectious disease. However, while it is highly sensitive at identifying bacteria, it does not provide information on the sensitivity of the organisms to antibiotics. The purpose of this study was to determine whether the results of mNGS can be used to guide optimization of culture methods to improve the sensitivity of culture from intraoperative samples. Methods. Between July 2014 and October 2019, patients with suspected
Aims. The French registry for complex bone and
Aims. Periprosthetic
Aims. The aim of this study was to further evaluate the accuracy of ten promising synovial biomarkers (bactericidal/permeability-increasing protein (BPI), lactoferrin (LTF), neutrophil gelatinase-associated lipocalin (NGAL), neutrophil elastase 2 (ELA-2), α-defensin, cathelicidin LL-37 (LL-37), human β-defensin (HBD-2), human β-defensin 3 (HBD-3), D-dimer, and procalcitonin (PCT)) for the diagnosis of periprosthetic